Dianthus Therapeutics (NASDAQ:DNTH – Get Free Report) is expected to be issuing its quarterly earnings data before the market ...

HC Wainwright reaffirmed their buy rating on shares of Dianthus Therapeutics (NASDAQ:DNTH – Free Report) in a report issued ...

Given this risk, we thought we'd take a look at whether Dianthus Therapeutics (NASDAQ:DNTH) shareholders should be worried about its cash burn. For the purposes of this article, c ...

Full Year 2024 Results Key Financial Results Net loss: US$85.0m (loss widened ...

Dianthus Therapeutics, Inc. (DNTH) came out with a quarterly loss of $0.81 per share versus the Zacks Consensus Estimate of a loss of $0.85. This compares to loss of $0.71 per share a year ago. These ...

Reports Q4 revenue $1.33M, consensus $859,700. “We remain on track to report top-line data in 2H’25 from our Phase 2 clinical trial of DNTH103 ...

Featured here, the Balance Sheet for Dianthus Therapeutics Inc, which summarizes the company's financial position including assets, liabilities and shareholder equity for each of the latest 10 period ...

NEW YORK - Dianthus Therapeutics, Inc. (NASDAQ:DNTH), a pharmaceutical company based in New York with a market capitalization of $588 million, has announced the departure of Tomas Kiselak from its ...

NEW YORK and WALTHAM, Mass. - Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a biotech firm focusing on antibody complement therapeutics for autoimmune diseases, with a current market capitalization of ...